An open-label multiyear study of sargramostim-treated Parkinson’s disease patients examining drug safety, tolerability, and immune biomarkers from limited case numbers

BACKGROUND: The clinical utility and safety of sargramostim has previously been reported in cancer, acute radiation syndrome, autoimmune disease, inflammatory conditions, and Alzheimer’s disease. The safety, tolerability, and mechanisms of action in Parkinson’s disease (PD) during extended use has n...

Descripción completa

Detalles Bibliográficos
Autores principales: Olson, Katherine E., Abdelmoaty, Mai M., Namminga, Krista L., Lu, Yaman, Obaro, Helen, Santamaria, Pamela, Mosley, R. Lee, Gendelman, Howard E.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201023/
https://www.ncbi.nlm.nih.gov/pubmed/37217980
http://dx.doi.org/10.1186/s40035-023-00361-1

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10201023/
https://www.ncbi.nlm.nih.gov/pubmed/37217980
http://dx.doi.org/10.1186/s40035-023-00361-1

Ejemplares similares